Methotrexate Pfizer (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a key cofactor in nucleotide synthesis. By limiting DNA, RNA, and protein production, it suppresses rapidly dividing cells such as immune cells and cancer cells, providing both anti‑inflammatory and antineoplastic effects.

The dosage of Methotrexate Pfizer is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Only a qualified healthcare professional should determine the appropriate dose and administration schedule.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and harm the infant.

To request Methotrexate Pfizer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Methotrexate is often considered a first‑line disease‑modifying antirheumatic drug (DMARD) because of its proven efficacy, oral or injectable options, and cost‑effectiveness. Compared with biologic agents, it has a broader safety profile but may require more laboratory monitoring for liver and blood‑cell effects.

Methotrexate Pfizer should be stored at 2‑8 °C in a refrigerator, protected from light, and kept in its original packaging. Do not freeze or shake the product, and ensure the temperature remains stable throughout storage and transport.

Methotrexate can be given via intra‑arterial, intramuscular, or intrathecal injection, depending on the clinical indication and prescribing physician’s judgment. The route, dose, and frequency are determined by the treating specialist and are tailored to each patient’s therapeutic needs.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to immunosuppression, bone‑marrow failure, and acute renal impairment. Patients should be monitored regularly for hepatic enzymes, lung function, blood counts, and renal parameters to detect these complications early.

Methotrexate Pfizer should be avoided in pregnant or breastfeeding individuals, patients with severe renal or hepatic impairment, those with known hypersensitivity to methotrexate, and patients receiving live vaccines without appropriate medical supervision.